Congress quietly gives corporations a $10B+ R&D tax break—retroactive to 2021
H.R. 1990 — American Innovation and R&D Competitiveness Act of 2025 · Filed by Ron Estes (R-KS) · 81 cosponsors · Introduced Mar 10, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends the tax code to allow companies to immediately deduct research and development expenses as business costs rather than capitalizing them over time, and to amortize certain R&D costs over at least 60 months at the company's election. It also modifies how the R&D tax credit interacts with these deductions, allowing companies to either claim the credit or take a deduction, but not both on the same expenses. The primary beneficiaries are corporations conducting research and development, who gain flexibility in timing tax deductions and can reduce their taxable income faster.
Why we flagged it
The bill's functional purpose is to provide tax relief for corporations conducting research and development by allowing immediate deductions and flexible amortization schedules. This is a targeted tax expenditure benefiting a specific corporate activity, not a broad public policy or regulatory reform.
What the text implies
- The retroactive effective date (December 31, 2021) means companies may claim refunds for R&D expenses already incurred in prior years, creating a one-time revenue loss spike that is not apparent from the bill's title.
- By allowing taxpayers to elect between claiming the R&D credit or taking a deduction (but not both), the bill creates a tax-planning opportunity for large corporations with sophisticated accounting to minimize total tax liability in ways unavailable to smaller firms.
The full analysis lists 4 implications of this text.
Who stands to gain
large technology companies; pharmaceutical corporations; aerospace and defense contractors